Compound ID | 965

Update compound information

BLI-489

Synonym(s): BLI 489  |  BLI489

Class: Beta-lactamase inhibitor

Agent Type: Semisynthetic; Small molecule; Direct acting; Antibiotic adjuvant;
Spectrum of activity: Gram-negative
Mechanism of action: Class A, class C, and class D beta-lactamases inhibitor
Combined with other compounds: Was tested with pipercillin in murine modelswhich demonstrated a similar level of efficacy as pipercillin:tazobactam
Description: Carbapenem-type
Institute where first reported: Wyeth Research (Pfizer, USA)
Year first mentioned: 2007
Highest development stage: Phase 1
Development status: Active
Reason dropped: Was in phase I trials with Wyeth, however, with Pfizer (purchased Wyeth in 2009) closed it's antibiotic research unit in 2011; Wyeth is now owned and a subsidiary of Pfizer
Chemical structure(s):
Click here for structure editor
Molecular weight: 327.29
Iso. SMILES: C1COCC2=NC(=CN21)/C=C/3\[C@@H]4N(C3=O)C(=CS4)C(=O)[O-].[Na+]
InChI Key: RFSWVJXWZXQOSW-ZDFSRXSCSA-M
Can. SMILES: C1COCC2=NC(=CN12)/C=C\3/C(=O)N4C(=CS[C@H]34)C(=O)[O-].[Na+]
InChI: InChI=1S/C13H11N3O4S.Na/c17-11-8(12-16(11)9(6-21-12)13(18)19)3-7-4-15-1-2-20-5-10(15)14-7;/h3-4,6,12H,1-2,5H2,(H,18,19);/q;+1/p-1/b8-3-;/t12-;/m1./s1
External links:
PubChem link: https://pubchem.ncbi.nlm.nih.gov/compound/23697683
Guide to Pharmacology: BLI-489 free acid
Citations:
  • http://aac.asm.org/content/53/2/370.short#fn-2
  • https://clinicaltrials.gov/ct2/show/NCT00894439

    • AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.